https://okogen.reportablenews.com daily 1.0 https://okogen.reportablenews.com/pr/okogen-acquires-ranpirnase-assets-and-intellectual-property-portfolio 2026-03-26T12:00:00Z monthly 0.5 https://okogen.reportablenews.com/pr/okogen-announces-regulatory-submission-to-cdsco-for-emerald-study-and-appointment-of-new-chief-medical-officer 2025-04-02T12:00:00Z monthly 0.5 https://okogen.reportablenews.com/pr/okogen-inc-secures-3-3m-to-advance-phase-2b-clinical-program-for-pink-eye-acute-infectious-conjunctivitis 2024-12-11T13:00:00Z monthly 0.5 https://okogen.reportablenews.com/pr/okogen-initiates-phase-iib-trial-for-pink-eye 2023-10-31T12:00:00Z monthly 0.5 https://okogen.reportablenews.com/pr/okogen-inc-announces-ophthalmology-industry-veteran-joshua-moriarty-as-new-chief-executive-officer 2022-03-08T11:30:21Z monthly 0.5 https://okogen.reportablenews.com/pr/safe-effective-and-dose-responsive-anti-viral-activity-of-okg-0301-in-patients-with-acute-adenoviral-conjunctivitis-phase-2-interim-analysis-results-from-ruby-clinical-trial 2021-04-29T10:28:26Z monthly 0.5 https://okogen.reportablenews.com/pr/okogen-initiates-phase-2-clinical-trial-ruby-of-okg-0301-in-patients-with-acute-adenoviral-conjunctivitis 2019-02-01T10:06:25Z monthly 0.5 https://okogen.reportablenews.com/pr/okogen-raises-10-million 2018-02-27T20:07:52Z monthly 0.5